Old friends, new ways: Revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes

J. Erik Busby, Christopher P Evans

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of review: Standard therapy for muscle-invasive bladder cancer is radical cystectomy and pelvic-lymph-node dissection. Because 50% of patients will die at 5 years as a result of micrometastases, improvements have been sought to increase the survival rates. Two specific approaches include administration of neoadjuvant chemotherapy or extending the boundaries of the lymph-node dissection. We reviewed the current literature to define present trends and studies that involve these adjunct treatments. Recent findings: The benefits of extended lymphadenectomy have been demonstrated by several groups. These include mapping nodal metastatic sites and defining the requisite number of nodes removed to optimize survival. Though not universal, it is frequently concluded that increasing the number of nodes removed improves survival without worse morbidity. Neoadjuvant chemotherapy has been proposed to eliminate occult cancer cells outside the margins of resection. Results have been variable and modest, though emerging data from the Southwest Oncology Group may further support such an approach and improve organ preservation. Summary: Extended lymphadenectomy has consistently shown benefit with minimal morbidity and should be considered - especially in cystectomy patients that are T3. The results from neoadjuvant chemotherapy are more modest. Further studies await further elucidation to confirm this.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalCurrent Opinion in Urology
Volume14
Issue number5
DOIs
StatePublished - Sep 2004

Fingerprint

Lymph Node Excision
Drug Therapy
Cystectomy
Organ Preservation
Morbidity
Neoplasm Micrometastasis
Survival
Urinary Bladder Neoplasms
Survival Rate
Muscles
Therapeutics
Neoplasms

Keywords

  • Bladder cancer
  • Extended lymphadenectomy
  • Lymph-node dissection
  • Neoadjuvant chemotherapy
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Old friends, new ways : Revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. / Busby, J. Erik; Evans, Christopher P.

In: Current Opinion in Urology, Vol. 14, No. 5, 09.2004, p. 251-257.

Research output: Contribution to journalArticle

@article{51e2dd2638724461a36e62b0acea9b5d,
title = "Old friends, new ways: Revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes",
abstract = "Purpose of review: Standard therapy for muscle-invasive bladder cancer is radical cystectomy and pelvic-lymph-node dissection. Because 50{\%} of patients will die at 5 years as a result of micrometastases, improvements have been sought to increase the survival rates. Two specific approaches include administration of neoadjuvant chemotherapy or extending the boundaries of the lymph-node dissection. We reviewed the current literature to define present trends and studies that involve these adjunct treatments. Recent findings: The benefits of extended lymphadenectomy have been demonstrated by several groups. These include mapping nodal metastatic sites and defining the requisite number of nodes removed to optimize survival. Though not universal, it is frequently concluded that increasing the number of nodes removed improves survival without worse morbidity. Neoadjuvant chemotherapy has been proposed to eliminate occult cancer cells outside the margins of resection. Results have been variable and modest, though emerging data from the Southwest Oncology Group may further support such an approach and improve organ preservation. Summary: Extended lymphadenectomy has consistently shown benefit with minimal morbidity and should be considered - especially in cystectomy patients that are T3. The results from neoadjuvant chemotherapy are more modest. Further studies await further elucidation to confirm this.",
keywords = "Bladder cancer, Extended lymphadenectomy, Lymph-node dissection, Neoadjuvant chemotherapy, Transitional cell carcinoma",
author = "Busby, {J. Erik} and Evans, {Christopher P}",
year = "2004",
month = "9",
doi = "10.1097/00042307-200409000-00002",
language = "English (US)",
volume = "14",
pages = "251--257",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Old friends, new ways

T2 - Revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes

AU - Busby, J. Erik

AU - Evans, Christopher P

PY - 2004/9

Y1 - 2004/9

N2 - Purpose of review: Standard therapy for muscle-invasive bladder cancer is radical cystectomy and pelvic-lymph-node dissection. Because 50% of patients will die at 5 years as a result of micrometastases, improvements have been sought to increase the survival rates. Two specific approaches include administration of neoadjuvant chemotherapy or extending the boundaries of the lymph-node dissection. We reviewed the current literature to define present trends and studies that involve these adjunct treatments. Recent findings: The benefits of extended lymphadenectomy have been demonstrated by several groups. These include mapping nodal metastatic sites and defining the requisite number of nodes removed to optimize survival. Though not universal, it is frequently concluded that increasing the number of nodes removed improves survival without worse morbidity. Neoadjuvant chemotherapy has been proposed to eliminate occult cancer cells outside the margins of resection. Results have been variable and modest, though emerging data from the Southwest Oncology Group may further support such an approach and improve organ preservation. Summary: Extended lymphadenectomy has consistently shown benefit with minimal morbidity and should be considered - especially in cystectomy patients that are T3. The results from neoadjuvant chemotherapy are more modest. Further studies await further elucidation to confirm this.

AB - Purpose of review: Standard therapy for muscle-invasive bladder cancer is radical cystectomy and pelvic-lymph-node dissection. Because 50% of patients will die at 5 years as a result of micrometastases, improvements have been sought to increase the survival rates. Two specific approaches include administration of neoadjuvant chemotherapy or extending the boundaries of the lymph-node dissection. We reviewed the current literature to define present trends and studies that involve these adjunct treatments. Recent findings: The benefits of extended lymphadenectomy have been demonstrated by several groups. These include mapping nodal metastatic sites and defining the requisite number of nodes removed to optimize survival. Though not universal, it is frequently concluded that increasing the number of nodes removed improves survival without worse morbidity. Neoadjuvant chemotherapy has been proposed to eliminate occult cancer cells outside the margins of resection. Results have been variable and modest, though emerging data from the Southwest Oncology Group may further support such an approach and improve organ preservation. Summary: Extended lymphadenectomy has consistently shown benefit with minimal morbidity and should be considered - especially in cystectomy patients that are T3. The results from neoadjuvant chemotherapy are more modest. Further studies await further elucidation to confirm this.

KW - Bladder cancer

KW - Extended lymphadenectomy

KW - Lymph-node dissection

KW - Neoadjuvant chemotherapy

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=4344574318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344574318&partnerID=8YFLogxK

U2 - 10.1097/00042307-200409000-00002

DO - 10.1097/00042307-200409000-00002

M3 - Article

C2 - 15300144

AN - SCOPUS:4344574318

VL - 14

SP - 251

EP - 257

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -